Ranitidine hydrochloride

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Glaxo Wellcome, Boehringer Ingelheim, Federal University of São Paulo

Conditions

Anesthesia ComplicationHIV InfectionsHealthyHemodynamic InstabilityIleus ParalyticNauseaPain, PostoperativeVomiting

Phase 1

The Effect of Stomach Acid on Foscarnet

CompletedNCT00000964

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 1990-10-31Target: 6Updated: 2021-10-29

Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers

CompletedNCT02195804

Boehringer IngelheimHealthy

Start: 2009-05-31Updated: 2014-07-21

Phase 2

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

CompletedNCT00002106

Glaxo WellcomeHIV Infections

Target: 104Updated: 2005-06-24

Phase 4

Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia

Federal University of São PauloAnesthesia Complication, Hemodynamic Instability, Ileus Paralytic +3

Start: 2016-11-30End: 2017-03-31Target: 40Updated: 2016-11-04